LINC02405: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02405

NCBI ID: G101927592

LINC02405

Other Name(s): long intergenic non-protein coding RNA 2405 | Long intergenic non-protein coding RNA 2405

LINC02405: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02405 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as having various functionalities, including the regulation of gene expression, DNA replication, and cell cycle progression. Its unique features, such as its ability to interact with protein-coding RNAs, its stable expression over different cell cycle stages, and its distinct expression patterns across various tissues and biological processes, make it an attractive candidate for further investigation as a drug target or biomarker.

Drug Target Potential

LINC02405 has been shown to play a critical role in various cellular processes, including cell growth, apoptosis, and stem cell maintenance. Its involvement in these processes makes it an attractive target for small molecules, big molecules, or a combination of both.

One of the key reasons for LINC02405's drug target potential is its unique expression pattern across different tissues and biological processes. LINC02405 is highly expressed in the brain, and its levels are decreasing with age, which suggests that it may be involved in the aging process. Additionally, LINC02405 is expressed in various cell types, including blood cells, liver cells, and pancreatic beta cells, which suggests that it may be involved in the development and maintenance of various diseases.

Furthermore, LINC02405 has been shown to play a role in cell apoptosis, which is a critical process for maintaining tissue homeostasis and eliminating damaged or dysfunctional cells. Its involvement in cell apoptosis may make it a potential target for drugs that aim to prevent or reverse apoptosis.

Biomarker Potential

LINC02405 has also been shown to act as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its expression patterns and functions in these diseases make it an attractive candidate for diagnostic or therapeutic applications.

For example, LINC02405 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that it may be a potential biomarker for these diseases and could be a target for drugs that aim to upregulate its expression.

Additionally, LINC02405 has been shown to be involved in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. Its expression patterns and functions in these diseases make it an attractive candidate for diagnostic or therapeutic applications.

In conclusion, LINC02405 is a long intergenic non-protein-coding RNA that has various functionalities, including the regulation of gene expression, DNA replication, and cell cycle progression. Its unique expression pattern and involvement in various diseases make it an attractive candidate for further investigation as a drug target or biomarker. Further studies are needed to fully understand its role in these processes and to determine its potential as a therapeutic approach.

Protein Name: Long Intergenic Non-protein Coding RNA 2405

The "LINC02405 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02405 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets